

**Clean set of claim 103**

103. (Amended) An isolated, enriched or purified immunogenic composition comprising:

one or more autologous target carcinoma or lymphoma cells which have been irradiated and treated in vitro wherein said target carcinoma or lymphoma cells express one or more primary or costimulatory T cell activation molecules at a level higher than the amount of primary or costimulatory T cell activation molecules expressed from carcinoma or lymphoma cells without treatment in a patient mammal;

one or more antibodies wherein said antibodies further bind to an antigenic binding site on the surface of said one or more target carcinoma or lymphoma cells;

one or more primary or costimulatory T cell activation molecules on the surface of T cells in said patient mammal; and

a bridge molecule binding said antibodies and said primary or costimulatory T cell activation molecules on the surface of T cells of said patient mammal.